BioXcel Therapeutics Overview
Valuation check: BTAI's ROE is 71.38%, above the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow71.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, BTAI shows a ROE of 71.38%. That is above the Healthcare sector average of 29.33%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 29.33%. BioXcel Therapeutics is at 71.38%, which is higher that average. That is roughly 143.4% above the sector mean. Use the comparison chart on this page to see how BTAI stacks up against individual peers as well.
Check the historical chart to see whether BTAI's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare BioXcel Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has BioXcel Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 71.38%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 29.33%, while BTAI is at 71.38%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
